Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

4 Jan 2011 07:00

RNS Number : 8214Y
ViaLogy PLC
04 January 2011
 



 

 

VIALOGY PLC.

January 4th 2011

ViaLogy reports key advances in QuantumRD market acceptance

Pasadena, January 4, 2011. ViaLogy PLC (LSE:VIY) makes the following announcements as part of a continuing effort to keep shareholders as fully informed of its progress as is permitted by publicity rules imposed by the company's clients or business partners.

ViaLogy has successfully completed its technology demonstration project on an offshore prospect for a global non-US major exploration and production company. Results have been acknowledged by the client as beyond the scope of conventional seismic processing and analysis technology, and as a potentially unique tool in reducing exploration and production risk. The client's evaluation was carried out using rigorous global services industry standards. The work marks the first application of ViaLogy's technology for an undersea prospect, and reinforces QuantumRD's value proposition for both complex offshore and onshore prospects. A second project is now underway for the same firm, this one focused on a key onshore prospect. In both cases the exploration problems were presented to ViaLogy after conventional seismic analysis techniques had been applied extensively.

In another important development, ViaLogy reports advanced discussions with a leading non-US national oil company, following its preliminary evaluation of QuantumRD, to apply the technology to an offshore prospect for full operational analysis and de-risking of expensive wells. This firm is looking to disruptive technologies for reducing risks in new, deeper fields and non-conventional formations.

ViaLogy will figure prominently this month at Geo India 2011, India's leading annual hydrocarbon exploration and production industry gathering in New Delhi. Due to interest sparked by the company's technology and its successes in the field, ViaLogy CTO Dr. Sandeep Gulati will present an invited keynote address. In addition ViaLogy geophysicists will conduct a two-day workshop on QuantumRD technology as a fundamental advance in seismic interferometry, a focus area of India's geophysical community. Presenting the technology to scientists and industry professionals comes at the request of a number of large Asian firms, and gives ViaLogy a select outreach opportunity.

Finally, strategic partnership discussions have begun with a leading O&G services company, following exploration of links with a number of such firms. If successful such a partnership could offer a near term path to access extensive global markets.

CEO Robert Dean said, "These and related activities have been our focus for some months, and they are key milestones in our strategy to accelerate and win the acceptance of QuantumRD in global markets. I am pleased with our progress, and we are doing our best to keep shareholders informed within the limitations imposed on us. Interest in the technology has been intense with the large firms we have chosen to work with. In all cases, in order to prove the unique value of QuantumRD, we have been presented with their hardest problems, which in itself should be an accelerated proving ground for the technology in some of the world's toughest exploration environments."

Mr. Dean points out that the gestation period from enquiry to technology acceptance takes considerably longer when dealing with supermajors and global oil exploration companies. "These complex businesses have techniques and processes already in place on which they base very large capital expenditure decisions," he said. "What we bring them in QuantumRD is a powerful risk reduction tool that complements and can be integrated with existing practices. Gaining user acceptance as a standard part of their operations is what takes time, and why they typically insist on demonstration projects and extended technical discussions."

Ends

For further information contact: 

ViaLogy

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 20-7107-8000

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery. ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRGDBBUGBGBX
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.